These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 28870034

  • 21. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
    Urakami T, Mine Y, Aoki M, Okuno M, Suzuki J.
    Endocr J; 2017 Feb 27; 64(2):133-140. PubMed ID: 27746408
    [Abstract] [Full Text] [Related]

  • 22. Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
    Aso Y, Suzuki K, Chiba Y, Sato M, Fujita N, Takada Y, Murano S, Kuroda H.
    Diabetes Res Clin Pract; 2017 Aug 27; 130():237-243. PubMed ID: 28651211
    [Abstract] [Full Text] [Related]

  • 23. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
    Russell-Jones D, Gall MA, Niemeyer M, Diamant M, Del Prato S.
    Nutr Metab Cardiovasc Dis; 2015 Oct 27; 25(10):898-905. PubMed ID: 26232910
    [Abstract] [Full Text] [Related]

  • 24. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T, Hövelmann U, Nosek L, Hermanski L, Bøttcher SG, Haahr H.
    Expert Opin Drug Metab Toxicol; 2015 Oct 27; 11(8):1193-201. PubMed ID: 26086190
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I, Pérez Manghi F, García-Hernández P, Norwood P, Lehmann L, Tarp-Johansen MJ, Buse JB, DUAL V Investigators.
    JAMA; 2016 Mar 01; 315(9):898-907. PubMed ID: 26934259
    [Abstract] [Full Text] [Related]

  • 30. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
    Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, Endahl L, Mathieu C, NN1250-3579 (BEGIN Once Long) Trial Investigators.
    Diabetes Care; 2012 Dec 01; 35(12):2464-71. PubMed ID: 23043166
    [Abstract] [Full Text] [Related]

  • 31. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
    Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Ocampo Francisco AM, Rana A, Zinman B, BEGIN: VICTOZA ADD-ON (NN1250-3948) study group.
    Diabetes Obes Metab; 2014 Jul 01; 16(7):636-44. PubMed ID: 24443830
    [Abstract] [Full Text] [Related]

  • 32. Meta-Analysis and Cost-Effectiveness Analysis of Insulin Glargine 100 U/mL Versus Insulin Degludec for the Treatment of Type 2 Diabetes in China.
    Su W, Li C, Zhang L, Lin Z, Tan J, Xuan J.
    Diabetes Ther; 2019 Oct 01; 10(5):1969-1984. PubMed ID: 31482483
    [Abstract] [Full Text] [Related]

  • 33. Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study.
    Koehler G, Heller S, Korsatko S, Roepstorff C, Rasmussen S, Haahr H, Pieber TR.
    Diabetologia; 2014 Jan 01; 57(1):40-9. PubMed ID: 24057153
    [Abstract] [Full Text] [Related]

  • 34. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).
    Rosenstock J, Hollander P, Bhargava A, Ilag LL, Pollom RK, Zielonka JS, Huster WJ, Prince MJ.
    Diabetes Obes Metab; 2015 Aug 01; 17(8):734-41. PubMed ID: 25931141
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
    Philis-Tsimikas A, Klonoff DC, Khunti K, Bajaj HS, Leiter LA, Hansen MV, Troelsen LN, Ladelund S, Heller S, Pieber TR, CONCLUDE Study Group.
    Diabetologia; 2020 Apr 01; 63(4):698-710. PubMed ID: 31984443
    [Abstract] [Full Text] [Related]

  • 38. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
    Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, Kvist K, Norwood P.
    JAMA; 2017 Jul 04; 318(1):45-56. PubMed ID: 28672317
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.
    Halberg IB, Lyby K, Wassermann K, Heise T, Zijlstra E, Plum-Mörschel L.
    Lancet Diabetes Endocrinol; 2019 Mar 04; 7(3):179-188. PubMed ID: 30679095
    [Abstract] [Full Text] [Related]

  • 40. Comparison of the Impact of Insulin Degludec U100 and Insulin Glargine U300 on Glycemic Variability and Oxidative Stress in Insulin-Naive Patients With Type 2 Diabetes Mellitus: Pilot Study for a Randomized Trial.
    Vrebalov Cindro P, Krnić M, Modun D, Vuković J, Tičinović Kurir T, Kardum G, Rušić D, Šešelja Perišin A, Bukić J.
    JMIR Form Res; 2022 Jul 08; 6(7):e35655. PubMed ID: 35802405
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.